Related Experiment Video
Updated: May 15, 2026

Cerebellar Regional Dissection for Molecular Analysis
Published on: December 5, 2020
Thiamine and spinocerebellar ataxia type 2
Antonio Costantini1, Maria Immacolata Pala, Marco Colangeli
1Department of Neurological Rehabilitation, Clinic Villa Immacolata, Viterbo, Italy. carapetata@libero.it
Abstract:
Spinocerebellar ataxia type 2 is a genetic disorder characterised by the degeneration of the cerebellum, its connections and degeneration in brainstem areas. Some observations indicate that high doses of thiamine may lead to the partial regression of the symptoms. One patient was under rehabilitative treatment from June 2011 to July 2012. We assessed the level of fatigue using the Fatigue Severity Scale. We performed the Scale for Assessment and Rating of Ataxia and Robertson Profile for Dysarthria (Italian version). Thiamine and thiamine pyrophosphate levels in the blood were within the healthy reference range. We started a parenteral therapy with 100 mg intramuscular every 7 days. The therapy led to a partial regression of fatigue within a few days. After about 3 months, a discreet improvement of motor symptoms especially in speech was observed. The symptoms could derive from a focal thiamine deficiency that could determine a selective neuronal loss.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
ATP Synthase: Mechanism
Alzheimer Disease ll: Pathophysiology
Secondary Spinal Cord Injury llI: Pathophysiology
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Hepatic Encephalopathy